Alan H. Bryce, MD, presented “Updates in PARP Inhibition and Germline Testing in Prostate Cancer” virtually during the 21st Annual Future Directions in Urology Symposium in August 2020.
How to cite: Bryce, Alan H. “Updates in PARP Inhibition and Germline Testing in Prostate Cancer” August 10th, 2020. Accessed Dec 2020. https://grandroundsinurology.com/updates-in-parp-inhibition-and-germline-testing-in-prostate-cancer/
Alan H. Bryce, MD, Medical Director of the Genomic Oncology Clinic at Mayo Clinic Arizona in Scottsdale, outlines recent treatment updates for prostate cancer patients, beginning with a brief review of germline testing recommendations. Following this, Dr. Bryce discusses two newly-approved PARP inhibitors that target mutations: rucaparib and olaparib. Dr. Bryce then poses a series of questions and challenges that physicians should consider as ongoing trials for various disease states and combinations (neoadjuvant, metastatic castrate sensitive prostate cancer, firstline metastatic castrate resistance prostate cancner, PARP inhibition + immunotherapy, etc.) continue.
About The 2020 Virtual Future Directions in Urology Symposium
The Future Directions in Urology Symposium was founded 21 years ago to reflect on the current state of the urology community and predict trends in the treatment of urology conditions in the following 5-10 years. This conference brings together experts in the field, including urologists, medical oncologists, radiation oncologists, family practice doctors, researchers, and industry leaders to review current trends and prospects. Dr. Bryce presented this lecture during this year’s virtual conference in August 2020.